Immuneering-logo (1).png
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 16:05 ET | Immuneering Corporation
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development...
Transparency Market Research
Non-Invasive Cancer Diagnostics Market Size & Share Surpass USD 207 billion by 2031, Growing at a CAGR of 7.0% - Exclusive Study by Transparency Market Research
October 19, 2023 11:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global non-invasive cancer diagnostics market is projected to flourish at a CAGR of 7.0%...
Noah Medical’s Galaxy System™ Named Finalist in 2023 Fierce Innovation Awards
October 19, 2023 08:00 ET | Noah Medical
Medical robotics innovator Noah Medical announced today that its Galaxy System was named a finalist in the 2023 Fierce Innovation Awards.
Emergen logo.png
Global Targeted Therapeutics Market Size to Reach USD 214.31 Billion in 2032 | Emergen Research
October 16, 2023 09:09 ET | Emergen Research
Vancouver, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Current Market Scenario (Market estimates) The global Targeted Therapeutics Market size was USD 93.75 Billion in 2020. Increasing prevalence of cancer,...
Immuneering-logo (1).png
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
October 12, 2023 16:05 ET | Immuneering Corporation
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...
Large-Cell and Other Lung Cancer in the United States: Patient Journey Infographic for All Race/Ethnicity Groups in 2022
Machine Learning Model Unveils Stunning Lung Cancer Risk Predictions
October 05, 2023 11:58 ET | Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- In a recent groundbreaking study published on October 3rd in the open access journal PLOS Medicine, Thomas Callender of University College London and his...
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
October 03, 2023 14:30 ET | Ocean Biomedical, Inc.
Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the company and Polar Multi-Strategy Master Fund (Polar), a significant long-time...
Vantage Market Research.png
Targeted Therapeutics Market Size & Share to Surpass $80.9 Billion by 2030 | Vantage Market Research
September 19, 2023 09:13 ET | Vantage Market Research
WASHINGTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Targeted Therapeutics Market has been steadily growing over the years due to the increasing prevalence of...
Global Lung Cancer Screening Market
Global Lung Cancer Screening Market Size and Forecast to 2030: The Cost Conundrum - Challenges Posed by High Lung Cancer Screening Test Expenses
September 19, 2023 08:48 ET | Research and Markets
Dublin, Sept. 19, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Screening Market Size and Forecast to 2030 - Global Analysis by Cancer Type [Non-Small Cell Lung Cancer and Small Cell Lung Cancer],...
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
September 07, 2023 22:43 ET | Burning Rock Biotech Limited
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal...